Targetable Biomimetic NIR-II Theranostic Nanoplatform for Highly Efficient Multimodal Imaging-Guided Photothermal Therapy of Cervical Cancer
Cervical cancer (CC) is still the fourth most common cause of cancer deaths in women. However, current biomedical imaging techniques exhibit inherent limitations in the diagnosis and treatment of CC. This study aims to develop a biomimetic nanoplatform based on tumor cell membranes, loaded with a palladium (Pd)-based computed tomography (CT) contrast agent and the near-infrared (NIR) fluorescent probe indocyanine green (ICG). This multifunctional nanoplatform is designed to integrate multimodal imaging with photothermal therapy (PTT), thereby improving the diagnostic accuracy and therapeutic efficacy against CC. In this study, biomimetic nanoparticles (NPs), designated as M@Pd-ICG NPs, were synthesized by encapsulating Pd and ICG within HeLa cell membranes derived from cell-derived xenograft (CDX) models. Subsequently, the toxicity, biocompatibility, and tumor suppression capability of the M@Pd-ICG NPs were evaluated in vitro. In vivo, the multimodal imaging performance of the M@Pd-ICG NPs and their photothermal therapeutic efficacy under 808-nm laser irradiation were investigated in mouse model bearing subcutaneous cervical tumor. The M@Pd-ICG NPs were successfully prepared and exhibited favorable stability, excellent photothermal conversion efficiency (34.04%), and good biocompatibility, enabling homologous targeting and prolonged circulation time. The M@Pd-ICG NPs integrated the complementary advantages of NIR-II fluorescence imaging (900-1700 nm, NIR-II FI), photothermal imaging (PTI), and CT imaging. Both in vitro and in vivo studies demonstrated that, under 808-nm laser irradiation, M@Pd-ICG NPs induced significant photothermal effects and tumor ablation. M@Pd-ICG NPs successfully integrate multimodal imaging and PTT, owing to their excellent targeting capability and good biocompatibility, demonstrating potential for further biomedical applications.
